QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:ASLN

ASLAN Pharmaceuticals Stock Forecast, Price & News

$3.52
+0.11 (+3.23 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.48
Now: $3.52▼
$3.89
50-Day Range
$1.83
MA: $2.58▼
$4.00
52-Week Range
$0.83
Now: $3.52▼
$4.28
Volume558,970 shs
Average Volume661,258 shs
Market Capitalization$133.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals logo

Headlines

ASLAN Pharmaceuticals Limited (ASLN)
January 27, 2021 |  uk.finance.yahoo.com
New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
January 26, 2021 |  finance.yahoo.com
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 |  finance.yahoo.com
Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs
January 6, 2021 |  finance.yahoo.com
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade
December 25, 2020 |  finance.yahoo.com
Intellia (NTLA) Catches Eye: Stock Jumps 7.8%
December 3, 2020 |  finance.yahoo.com
ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher
December 1, 2020 |  finance.yahoo.com
Is ASLAN Pharmaceuticals Limited (ASLN) A Good Stock To Buy?
November 29, 2020 |  finance.yahoo.com
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
November 27, 2020 |  finance.yahoo.com
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
November 24, 2020 |  finance.yahoo.com
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
November 24, 2020 |  finance.yahoo.com
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
November 24, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.aslanpharma.com
Phone65-6222-4235
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.08
Quick Ratio2.08

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3 million
Price / Sales44.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.02) per share
Price / Book-176.00

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-47,020,000.00
Net MarginsN/A
Return on Equity-10,427.34%
Return on Assets-97.68%

Miscellaneous

Outstanding Shares37,991,000
Market Cap$133.73 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.16 out of 5 stars

Medical Sector

877th out of 1,958 stocks

Pharmaceutical Preparations Industry

433rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.52
+0.11 (+3.23 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ASLAN Pharmaceuticals (NASDAQ:ASLN) Frequently Asked Questions

Is ASLAN Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than ASLAN Pharmaceuticals?

Wall Street analysts have given ASLAN Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ASLAN Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 12,800 shares, an increase of 276.5% from the January 14th total of 3,400 shares. Based on an average trading volume of 475,100 shares, the days-to-cover ratio is presently 0.0 days.
View ASLAN Pharmaceuticals' Short Interest.

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for ASLAN Pharmaceuticals.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings data on Saturday, November, 14th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01.
View ASLAN Pharmaceuticals' earnings history.

How has ASLAN Pharmaceuticals' stock been impacted by Coronavirus?

ASLAN Pharmaceuticals' stock was trading at $1.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASLN shares have increased by 121.4% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ASLN?

1 analysts have issued 1-year target prices for ASLAN Pharmaceuticals' shares. Their forecasts range from $5.00 to $6.00. On average, they expect ASLAN Pharmaceuticals' stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:
  • Dr. Carl Alan Jason Morton Firth, CEO & Exec. Director (Age 48)
  • Mr. Kiran Kumar Asarpota, Chief Operating Officer (Age 42)
  • Mr. Ben Goodger, Gen. Counsel (Age 58)
  • Charlie Hsu, Investor Relations Director
  • Chi-Chin Wang, IR & Corp. Devel. Director
  • Ms. Alison Ward, Chief Devel. Officer
  • Mr. Stephen Doyle, Chief Bus. Officer (Age 48)
  • Dr. Kenneth Kobayashi, Chief Medical Officer

Who are some of ASLAN Pharmaceuticals' key competitors?

Some companies that are related to ASLAN Pharmaceuticals include CorMedix (CRMD), Clovis Oncology (CLVS), Urovant Sciences (UROV), Viking Therapeutics (VKTX), Amryt Pharma (AMYT), Syros Pharmaceuticals (SYRS), Neoleukin Therapeutics (NLTX), Inozyme Pharma (INZY), Spero Therapeutics (SPRO), Homology Medicines (FIXX), Crinetics Pharmaceuticals (CRNX), Avadel Pharmaceuticals (AVDL), BeyondSpring (BYSI), SIGA Technologies (SIGA) and Kala Pharmaceuticals (KALA).
View all of ASLN's competitors.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

Who are ASLAN Pharmaceuticals' major shareholders?

ASLAN Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (6.26%), Temasek Holdings Private Ltd (5.24%) and Renaissance Technologies LLC (1.01%).

Which institutional investors are buying ASLAN Pharmaceuticals stock?

ASLN stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Temasek Holdings Private Ltd, and Renaissance Technologies LLC.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $3.52.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals has a market capitalization of $133.73 million and generates $3 million in revenue each year. The company earns $-47,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is ASLAN Pharmaceuticals' official website?

The official website for ASLAN Pharmaceuticals is www.aslanpharma.com.

Where are ASLAN Pharmaceuticals' headquarters?

ASLAN Pharmaceuticals is headquartered at 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.